Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Total Valuation
Karyopharm Therapeutics has a market cap or net worth of $169.68M. The enterprise value is $261.37M.
Market Cap$169.68M
Enterprise Value$261.37M
Share Statistics
Karyopharm Therapeutics has 18,343,967 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,343,967
Owned by Insiders4.46%
Owned by Institutions10.57%
Financial Efficiency
Karyopharm Therapeutics’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -236.62%.
Return on Equity (ROE)0.67
Return on Assets (ROA)-1.81
Return on Invested Capital (ROIC)-236.62%
Return on Capital Employed (ROCE)-5.55
Revenue Per Employee523.54K
Profits Per Employee-702.65K
Employee Count279
Asset Turnover1.35
Inventory Turnover1.47
Valuation Ratios
The current PE Ratio of Karyopharm Therapeutics is ―. Karyopharm Therapeutics’s PEG ratio is -0.00453.
PE Ratio―
PS Ratio0.55
PB Ratio-0.27
Price to Fair Value-0.27
Price to FCF-1.07
Price to Operating Cash Flow-2.31
PEG Ratio-0.00453
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of 146.07M and earned -196.04M in profits. Earnings per share was -17.93.
Revenue146.07M
Gross Profit140.12M
Operating Income-90.71M
Pretax Income-196.00M
Net Income-196.04M
EBITDA-90.41M
Earnings Per Share (EPS)-17.93
Cash Flow
In the last 12 months, operating cash flow was -75.37M and capital expenditures 0.00, giving a free cash flow of -75.37M billion.
Operating Cash Flow-75.37M
Free Cash Flow-75.37M
Free Cash Flow per Share-4.11
Dividends & Yields
Karyopharm Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.17
52-Week Price Change8.30%
50-Day Moving Average7.21
200-Day Moving Average5.83
Relative Strength Index (RSI)71.78
Average Volume (3m)228.24K
Important Dates
Karyopharm Therapeutics upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Karyopharm Therapeutics as a current ratio of 1.12, with Debt / Equity ratio of -81.71%
Current Ratio1.12
Quick Ratio1.08
Debt to Market Cap3.72
Net Debt to EBITDA-1.98
Interest Coverage Ratio-1.98
Taxes
In the past 12 months, Karyopharm Therapeutics has paid 43.00K in taxes.
Income Tax43.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Karyopharm Therapeutics EV to EBITDA ratio is -2.87, with an EV/FCF ratio of -3.44.
EV to Sales1.78
EV to EBITDA-2.87
EV to Free Cash Flow-3.44
EV to Operating Cash Flow-3.44
Balance Sheet
Karyopharm Therapeutics has $63.74M in cash and marketable securities with $239.35M in debt, giving a net cash position of -$175.61M billion.
Cash & Marketable Securities$63.74M
Total Debt$239.35M
Net Cash-$175.61M
Net Cash Per Share-$9.57
Tangible Book Value Per Share-$26.79
Margins
Gross margin is 95.93%, with operating margin of -62.10%, and net profit margin of -134.21%.
Gross Margin95.93%
Operating Margin-62.10%
Pretax Margin-134.18%
Net Profit Margin-134.21%
EBITDA Margin-61.90%
EBIT Margin-62.10%
Analyst Forecast
The average price target for Karyopharm Therapeutics is $16.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.67
Price Target Upside72.39% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-3.98%
EPS Growth Forecast-29.94%